Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-Complex in Advanced Melanoma and Gynecologic Cancers
NCT02020707Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2014
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel and bevacizumab in melanoma, Cervical Cancer (CC), endometrial cancer (EC) and 3 more, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2014; status: completed.
02
Drugs
paclitaxelbevacizumab
03
Conditions
melanomaCervical Cancer (CC)endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02020707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020707.